AR119673A1 - Compuestos bicíclicos de cetona y métodos para utilizarlos - Google Patents
Compuestos bicíclicos de cetona y métodos para utilizarlosInfo
- Publication number
- AR119673A1 AR119673A1 ARP200100056A ARP200100056A AR119673A1 AR 119673 A1 AR119673 A1 AR 119673A1 AR P200100056 A ARP200100056 A AR P200100056A AR P200100056 A ARP200100056 A AR P200100056A AR 119673 A1 AR119673 A1 AR 119673A1
- Authority
- AR
- Argentina
- Prior art keywords
- formula
- pyrrolo
- dihydro
- triazol
- fluoro
- Prior art date
Links
- -1 KETONE COMPOUNDS Chemical class 0.000 title abstract 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 4
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 3
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 abstract 3
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 3
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 abstract 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 125000005843 halogen group Chemical group 0.000 abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 125000001424 substituent group Chemical group 0.000 abstract 2
- CLELLYLGVVWSNC-UHFFFAOYSA-N (2,2-dimethyl-3-oxabicyclo[3.1.0]hexan-1-yl)-(7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl)methanone Chemical compound CC1(C)OCC(C2)C12C(C1=NN(C(CC2F)C3=CC=CC=C3)C2=N1)=O CLELLYLGVVWSNC-UHFFFAOYSA-N 0.000 abstract 1
- NAWXUBYGYWOOIX-SFHVURJKSA-N (2s)-2-[[4-[2-(2,4-diaminoquinazolin-6-yl)ethyl]benzoyl]amino]-4-methylidenepentanedioic acid Chemical compound C1=CC2=NC(N)=NC(N)=C2C=C1CCC1=CC=C(C(=O)N[C@@H](CC(=C)C(O)=O)C(O)=O)C=C1 NAWXUBYGYWOOIX-SFHVURJKSA-N 0.000 abstract 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 1
- 125000004767 (C1-C4) haloalkoxy group Chemical group 0.000 abstract 1
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 abstract 1
- 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 abstract 1
- FBORMSYFVQSNPV-UHFFFAOYSA-N 1-[7-fluoro-5-(1-methylpyrazol-4-yl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]propan-1-one Chemical compound CCC(=O)C1=NN2C(CC(C2=N1)F)C3=CN(N=C3)C FBORMSYFVQSNPV-UHFFFAOYSA-N 0.000 abstract 1
- 125000001731 2-cyanoethyl group Chemical group [H]C([H])(*)C([H])([H])C#N 0.000 abstract 1
- UBGABCPJLOUPOD-UHFFFAOYSA-N CC(C)(CO)C(C1=NN(C(CC2F)C3=CC=CC=C3)C2=N1)=O Chemical compound CC(C)(CO)C(C1=NN(C(CC2F)C3=CC=CC=C3)C2=N1)=O UBGABCPJLOUPOD-UHFFFAOYSA-N 0.000 abstract 1
- ZQVFZBINUZNLET-UHFFFAOYSA-N CC(C)(COC(F)F)C(C1=NN(C(CC2F)C3=CC=CC=C3)C2=N1)=O Chemical compound CC(C)(COC(F)F)C(C1=NN(C(CC2F)C3=CC=CC=C3)C2=N1)=O ZQVFZBINUZNLET-UHFFFAOYSA-N 0.000 abstract 1
- MSWPUSCLYLQSOD-KBPBESRZSA-N CC(N(C1)CC1C(C1=NN([C@@H](C[C@@H]2F)C3=CC=CC=C3)C2=N1)=O)=O Chemical compound CC(N(C1)CC1C(C1=NN([C@@H](C[C@@H]2F)C3=CC=CC=C3)C2=N1)=O)=O MSWPUSCLYLQSOD-KBPBESRZSA-N 0.000 abstract 1
- RYFGSKWVGYBXNB-UHFFFAOYSA-N N#CC1=CC(C(C2)N3N=C(C(C4CC4)=O)N=C3C2F)=CC=C1 Chemical compound N#CC1=CC(C(C2)N3N=C(C(C4CC4)=O)N=C3C2F)=CC=C1 RYFGSKWVGYBXNB-UHFFFAOYSA-N 0.000 abstract 1
- UCBCDYATPTZCCC-UHFFFAOYSA-N [5-(3-chlorophenyl)-7-fluoro-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]-cyclopropylmethanone Chemical compound C1CC1C(=O)C2=NN3C(CC(C3=N2)F)C4=CC(=CC=C4)Cl UCBCDYATPTZCCC-UHFFFAOYSA-N 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 229910052794 bromium Inorganic materials 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 abstract 1
- 229910052801 chlorine Inorganic materials 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- ADJGHHDLGNZOCP-UHFFFAOYSA-N cyclopropyl-(7-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl)methanone Chemical compound C1CC1C(=O)C2=NN3CCC(C3=N2)C4=CC=CC=C4 ADJGHHDLGNZOCP-UHFFFAOYSA-N 0.000 abstract 1
- HXHYIBLISMREFM-GHMZBOCLSA-N cyclopropyl-[(5R,7R)-7-fluoro-5-(5-fluoropyridin-3-yl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]methanone Chemical compound C1CC1C(=O)C2=NN3[C@H](C[C@H](C3=N2)F)C4=CC(=CN=C4)F HXHYIBLISMREFM-GHMZBOCLSA-N 0.000 abstract 1
- HXHYIBLISMREFM-QWRGUYRKSA-N cyclopropyl-[(5S,7S)-7-fluoro-5-(5-fluoropyridin-3-yl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]methanone Chemical compound C1CC1C(=O)C2=NN3[C@@H](C[C@@H](C3=N2)F)C4=CC(=CN=C4)F HXHYIBLISMREFM-QWRGUYRKSA-N 0.000 abstract 1
- HXHYIBLISMREFM-UHFFFAOYSA-N cyclopropyl-[7-fluoro-5-(5-fluoropyridin-3-yl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]methanone Chemical compound C1CC1C(=O)C2=NN3C(CC(C3=N2)F)C4=CC(=CN=C4)F HXHYIBLISMREFM-UHFFFAOYSA-N 0.000 abstract 1
- 229910052731 fluorine Inorganic materials 0.000 abstract 1
- 125000004438 haloalkoxy group Chemical group 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 abstract 1
- 125000003226 pyrazolyl group Chemical group 0.000 abstract 1
- 125000004076 pyridyl group Chemical group 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Transplantation (AREA)
- Psychology (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962791118P | 2019-01-11 | 2019-01-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR119673A1 true AR119673A1 (es) | 2022-01-05 |
Family
ID=69528972
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP200100056A AR119673A1 (es) | 2019-01-11 | 2020-01-09 | Compuestos bicíclicos de cetona y métodos para utilizarlos |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US12344612B2 (https=) |
| EP (1) | EP3908586B1 (https=) |
| JP (1) | JP7585205B2 (https=) |
| CN (1) | CN113302193A (https=) |
| AR (1) | AR119673A1 (https=) |
| TW (1) | TW202043229A (https=) |
| WO (1) | WO2020146615A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4313986A1 (en) * | 2021-04-02 | 2024-02-07 | Genentech, Inc. | Processes for making bicyclic ketone compounds |
| WO2023225041A1 (en) | 2022-05-19 | 2023-11-23 | Merck Sharp & Dohme Llc | Ripk1 inhibitors and methods of use |
Family Cites Families (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1620508A1 (de) | 1965-07-23 | 1969-09-18 | Thomae Gmbh Dr K | Verfahren zur Herstellung neuer 4,5,6,7-Tetrahydrothiazolo-[5,4-c]-pyridine |
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US3948903A (en) | 1972-12-15 | 1976-04-06 | Parke, Davis & Company | Substituted N-(1,2-dihydro-2-oxonicotinyl)-cephalexins and -cephaloglycins |
| US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| EP0102324A3 (de) | 1982-07-29 | 1984-11-07 | Ciba-Geigy Ag | Lipide und Tenside in wässriger Phase |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| HUT35524A (en) | 1983-08-02 | 1985-07-29 | Hoechst Ag | Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance |
| GB8610530D0 (en) | 1986-04-30 | 1986-06-04 | Fbc Ltd | Herbicides |
| US5004697A (en) | 1987-08-17 | 1991-04-02 | Univ. Of Ca | Cationized antibodies for delivery through the blood-brain barrier |
| US5112596A (en) | 1990-04-23 | 1992-05-12 | Alkermes, Inc. | Method for increasing blood-brain barrier permeability by administering a bradykinin agonist of blood-brain barrier permeability |
| US5268164A (en) | 1990-04-23 | 1993-12-07 | Alkermes, Inc. | Increasing blood-brain barrier permeability with permeabilizer peptides |
| ATE191853T1 (de) | 1992-07-27 | 2000-05-15 | Us Health | Zielgerichte liposome zur blut-hirne schranke |
| US6080772A (en) | 1995-06-07 | 2000-06-27 | Sugen, Inc. | Thiazole compounds and methods of modulating signal transduction |
| EP1007042A4 (en) | 1997-06-13 | 2001-07-04 | Sugen Inc | NEW HETEROCYCLIC COMPOUNDS FOR MODULATING THE PROTEIN-TYROSIN-ENZYME-RELATED CELLULAR SIGNAL TRANSDUCTION |
| WO2001058869A2 (en) | 2000-02-11 | 2001-08-16 | Bristol-Myers Squibb Company | Cannabinoid receptor modulators, their processes of preparation, and use of cannabinoid receptor modulators in treating respiratory and non-respiratory diseases |
| US6514221B2 (en) | 2000-07-27 | 2003-02-04 | Brigham And Women's Hospital, Inc. | Blood-brain barrier opening |
| US20020065259A1 (en) | 2000-08-30 | 2002-05-30 | Schatzberg Alan F. | Glucocorticoid blocking agents for increasing blood-brain barrier permeability |
| US7034036B2 (en) | 2000-10-30 | 2006-04-25 | Pain Therapeutics, Inc. | Inhibitors of ABC drug transporters at the blood-brain barrier |
| DE10121982B4 (de) | 2001-05-05 | 2008-01-24 | Lts Lohmann Therapie-Systeme Ag | Nanopartikel aus Protein mit gekoppeltem Apolipoprotein E zur Überwindung der Blut-Hirn-Schranke und Verfahren zu ihrer Herstellung |
| JP4202250B2 (ja) | 2001-07-25 | 2008-12-24 | バイオマリン ファーマシューティカル インコーポレイテッド | 血液脳関門輸送を調節するための組成物および方法 |
| US20030162695A1 (en) | 2002-02-27 | 2003-08-28 | Schatzberg Alan F. | Glucocorticoid blocking agents for increasing blood-brain barrier permeability |
| KR101050700B1 (ko) | 2002-08-26 | 2011-07-20 | 다케다 야쿠힌 고교 가부시키가이샤 | 칼슘 수용체 조절 화합물 및 이의 용도 |
| CN101284136A (zh) | 2002-12-03 | 2008-10-15 | 布朗歇特洛克菲勒神经科学研究所 | 传输物质穿过血脑屏障的人工低密度脂蛋白载体 |
| ATE410161T1 (de) | 2003-05-02 | 2008-10-15 | Elan Pharm Inc | 4-bromo-5-(2-chloro-benzoylamino)-1h-pyrazol-3- carbonsäureamid-derivate und verwandte verbindungen als bradykinin b1 rezeptor antagonisten zur behandlung von entzündlichen erkrankungen |
| US20050089473A1 (en) | 2003-09-10 | 2005-04-28 | Cedars-Sinai Medical Center | Potassium channel mediated delivery of agents through the blood-brain barrier |
| EP2083009A1 (de) | 2008-01-22 | 2009-07-29 | Grünenthal GmbH | Substituierte Tethrahydroimidazopyridin-Verbindungen und deren Verwendung in Arzneimitteln |
| RU2628616C2 (ru) | 2011-11-03 | 2017-08-21 | Ф. Хоффманн-Ля Рош Аг | Бициклические соединения пиперазина |
| EP2852584B1 (en) | 2012-05-22 | 2018-02-28 | F. Hoffmann-La Roche AG | Substituted dipyridylamines and uses thereof |
| CA2896187A1 (en) | 2013-01-18 | 2014-07-24 | F. Hoffmann-La Roche Ag | 3-substituted pyrazoles and use as dlk inhibitors |
| TWI648274B (zh) | 2013-02-15 | 2019-01-21 | 英商葛蘭素史克智慧財產發展有限公司 | 作為激酶抑制劑之雜環醯胺類 （二） |
| PH12019502378A1 (en) | 2013-05-01 | 2022-05-11 | Hoffmann La Roche | Biheteroaryl compounds and uses thereof |
| CA2907912A1 (en) | 2013-05-01 | 2014-11-06 | F. Hoffmann-La Roche Ag | C-linked heterocycloalkyl substituted pyrimidines and their uses |
| WO2015006280A1 (en) | 2013-07-10 | 2015-01-15 | Vertex Pharmaceuticals Incorporated | Fused piperidine amides as modulators of ion channels |
| MX2016008110A (es) | 2013-12-20 | 2016-08-19 | Hoffmann La Roche | Derivados de pirazol como inhibidores de la cinasa de cremallera de leucina dual (dlk) y usos de los mismos. |
| WO2015144609A1 (en) | 2014-03-26 | 2015-10-01 | F. Hoffmann-La Roche Ag | Condensed [1,4]diazepine compounds as autotaxin (atx) and lysophosphatidic acid (lpa) production inhibitors |
| RU2017109122A (ru) | 2014-08-21 | 2018-09-21 | Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед | Способы лечения с использованием гетероциклических амидов в качестве ингибиторов киназы |
| WO2016142310A1 (en) | 2015-03-09 | 2016-09-15 | F. Hoffmann-La Roche Ag | Tricyclic dlk inhibitors and uses thereof |
| TWI730959B (zh) | 2015-05-19 | 2021-06-21 | 英商葛蘭素史克智慧財產發展有限公司 | 作為激酶抑制劑之雜環醯胺 |
| TWI763630B (zh) * | 2015-07-02 | 2022-05-11 | 瑞士商赫孚孟拉羅股份公司 | 雙環內醯胺及其使用方法 |
| CN108602809B (zh) * | 2015-12-04 | 2022-09-30 | 戴纳立制药公司 | 异噁唑烷衍生的受体相互作用蛋白激酶1(ripk 1)的抑制剂 |
| WO2017109724A1 (en) | 2015-12-21 | 2017-06-29 | Glaxosmithkline Intellectual Property Development Limited | Heterocyclic amides as kinase inhibitors |
| MA44007A (fr) | 2016-02-05 | 2018-12-19 | Denali Therapeutics Inc | Inhibiteurs du récepteur interagissant avec protéine kinase 1 |
| US11180493B2 (en) * | 2016-11-08 | 2021-11-23 | Cyclerion Therapeutics, Inc. | SGC stimulators |
| US11071721B2 (en) | 2016-12-02 | 2021-07-27 | Genentech, Inc. | Bicyclic amide compounds and methods of use thereof |
| US11072607B2 (en) * | 2016-12-16 | 2021-07-27 | Genentech, Inc. | Inhibitors of RIP1 kinase and methods of use thereof |
| US11098058B2 (en) * | 2017-07-14 | 2021-08-24 | Genentech, Inc. | Bicyclic ketone compounds and methods of use thereof |
| PE20211246A1 (es) * | 2017-10-11 | 2021-07-13 | Hoffmann La Roche | Compuestos biciclicos para su uso como inhibidores de rip1 quinasa |
| SG11202002877RA (en) | 2017-10-31 | 2020-04-29 | Hoffmann La Roche | Bicyclic sulfones and sulfoxides and methods of use thereof |
-
2020
- 2020-01-09 CN CN202080008933.9A patent/CN113302193A/zh active Pending
- 2020-01-09 AR ARP200100056A patent/AR119673A1/es unknown
- 2020-01-09 WO PCT/US2020/012908 patent/WO2020146615A1/en not_active Ceased
- 2020-01-09 EP EP20704652.5A patent/EP3908586B1/en active Active
- 2020-01-09 JP JP2021539523A patent/JP7585205B2/ja active Active
- 2020-01-09 TW TW109100698A patent/TW202043229A/zh unknown
-
2021
- 2021-07-08 US US17/371,001 patent/US12344612B2/en active Active
-
2025
- 2025-05-23 US US19/217,418 patent/US20250282788A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP3908586B1 (en) | 2022-12-21 |
| US20250282788A1 (en) | 2025-09-11 |
| JP2022516651A (ja) | 2022-03-01 |
| US20210340151A1 (en) | 2021-11-04 |
| CN113302193A (zh) | 2021-08-24 |
| EP3908586A1 (en) | 2021-11-17 |
| TW202043229A (zh) | 2020-12-01 |
| WO2020146615A1 (en) | 2020-07-16 |
| JP7585205B2 (ja) | 2024-11-18 |
| US12344612B2 (en) | 2025-07-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20161388A1 (es) | Inhibidores de la jak1 para el tratamiento de sindromes mielodisplasicos | |
| PE20220592A1 (es) | Inhibidores de la autofagia de heteroarilaminopirimidina amida y metodos de uso de estos | |
| JP2020515575A5 (https=) | ||
| AR097388A1 (es) | Beneficio de supervivencia en pacientes con tumores sólidos con niveles elevados de proteína c reactiva | |
| RU2018140092A (ru) | Новые пиразолпиримидиновые производные | |
| EP4295852A3 (en) | Piperidine derivatives as inhibitors of cyclin dependent kinase 7 (cdk7) | |
| PE20180530A1 (es) | Derivados de amidas policiclicas como inhibidores de cdk9 | |
| AR080688A1 (es) | Derivados de 2,3-dihidro-1h-inden-1-il-2,7-diazaspiro[3.5]nonano como agonistas o antagonistas inversos de grelina | |
| AR102852A1 (es) | Inhibidores heterocíclicos de la calicreína plasmática | |
| JP2016519156A5 (https=) | ||
| AR067965A2 (es) | Compuestos que contienen lactama inhibidores del factor x de coagulacion, composiciones farmaceuticas que los contienen y usos de los mismos en el tratamiento de trastornos tromboenmbolicos. | |
| AR103064A1 (es) | Compuestos moduladores de fxr (nr1h4) | |
| CO6160237A2 (es) | Pirazinonas y pirazinoles sustituidos y composiciones que los comprenden | |
| PE20190811A1 (es) | Derivados de pirazolopirimidinas como inhibidor de quinasa | |
| PE20171514A1 (es) | Heterociclos biciclicos como inhibidores de fgfr | |
| IL258577A (en) | 2,4-dihydroxy-nicotinamides as apj agonists | |
| AR119673A1 (es) | Compuestos bicíclicos de cetona y métodos para utilizarlos | |
| MX2017016772A (es) | Metodo para producir un derivado de 7h-pirrolo[2,3-d]pirimidina e intermediario del mismo. | |
| AR106778A1 (es) | Derivados heterocíclicos activos como plaguicidas con sustituyentes que contienen azufre y ciclopropilo | |
| EA202091761A1 (ru) | Комбинированная терапия для лечения гастроинтестинальных стромальных опухолей | |
| RU2019119899A (ru) | Новое дизамещенное 1,2,4-триазиновое соединение | |
| AR055074A1 (es) | Derivados de heteroaril benzamidas como activadores de glk en el tratamiento de diabetes. procesos de obtencion y composiciones farmaceuticas. | |
| JP2016531950A5 (ja) | 複素環化合物 | |
| AR111251A1 (es) | Herbicidas de piridazinona | |
| RU2016117732A (ru) | Антагонисты рецептора соматостатина подтипа 5 (sstr5) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |